

Bone Mineral Density Studies

Policy MP-041

Origination Date: 08/28/2024

Reviewed/Revised Date: 08/28/2024

Next Review Date: 08/28/2025

Current Effective Date: 10/28/2024

Disclaimer:

1. Policies are subject to change in accordance with State and Federal notice requirements.
2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the "Policy" section for more information.
3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained.
4. **This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member's plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy.**

Description:

Osteoporosis is a systemic, progressive skeletal disease characterized by low bone mass and microarchitectural tissue deterioration, leading to bone fragility and increased risk of fracture. The term low bone mass is used interchangeably with low bone mineral density (BMD). Osteoporosis is common and can have serious consequences. For example, the worldwide risk of hip fracture is 1 in 3 for women 50 years of age or older and osteoporotic hip fracture increases the risk of mortality in the year following fracture. Any osteoporotic fracture predicts future fracture. Early detection of osteopenia or osteoporosis is important so that drugs and other therapies can be used to reduce the incidence of fragility fractures.

Dual-energy x-ray absorptiometry (DEXA) is the most commonly used technique to measure BMD because of its ease of use, low radiation exposure, and its ability to measure BMD at both the hip and spine. Earlier technologies, such as single and dual photon absorptiometry are rarely used and dual photon absorptiometry is considered obsolete. DEXA is the gold standard for bone quality measurement in children as well as adults, due to precision, reproducibility, and availability of standardized data. Nevertheless, DEXA is not without limitations. Disrupting factors such as movement during measurement, contractures, metallic implants, and sometimes even scoliosis can cause results to be uninterpretable.

Trabecular bone score (TBS) is calculated with proprietary software called TBS iNsign (Medimaps Group) and represents a measure of bone microarchitecture quality. The TBS value is derived from imaging data produced by a standard lumbar spine DEXA scan. TBS is not

intended to replace BMD measurements or scores derived from fracture risk tools but rather to add complementary information and thereby improve risk assessment, treatment selection, and treatment monitoring. TBS is correlated with 3-dimensional bone microarchitecture parameters independent of its correlation with BMD. Lower TBS values are associated with previous fragility (osteoporosis-related) fracture regardless of whether BMD values meet the diagnostic criteria for osteoporosis or osteopenia.

Ultrasound-based Radiofrequency Echographic Multi-spectrometry (REMS) is a non-ionizing technology that evaluates bone status by analyzing raw, unfiltered native ultrasound signals, so-called radio frequency (RF) ultrasound signals, obtained during an ultrasound scan of the lumbar vertebrae and proximal femur. The analysis of native unfiltered ultrasound signals allows for information about the characteristics of bone tissue to be acquired. Bone density is obtained by comparing the spectra of analyzed signal with reference spectral models that have been previously obtained. REMS scans are performed at both the proximal femur and lumbar spine.

Policy Statement and Criteria

1. Commercial Plans/CHIP

U of U Health Plans considers central dual-energy x-ray absorptiometry (DEXA scan) (77080) medically necessary when used as a screening tool for osteoporosis with any of the following indications:

- A. Women aged ≥ 65 years
- B. Postmenopausal women ≤ 65 years of age who have one of the following risk factors:
 - i. Menopause, natural or surgical, before age 40
 - ii. History of non-traumatic fracture after age 45 in a first-degree relative
 - iii. Current smoker (one pack or more per day)
 - iv. On no hormone replacement therapy OR on hormone replacement therapy greater than 10-15 years
- C. Women ≥ 65 years of age whose fracture risk is at least equal to that of an average risk 65 year old woman according to the FRAX (Fracture Risk Assessment) tool
- D. Men aged ≥ 50 years with at least one factor related to an increased risk of osteoporosis (i.e., aged ≥ 70 years, low body weight, weight loss $> 10\%$, physical inactivity, corticosteroid use, androgen deprivation therapy, gonadal insufficiency (primary and secondary) (includes androgen suppression) and previous fragility fracture)

U of U Health Plans does NOT cover bone mineral density measurement when screening for osteoporosis for any other population as it is considered experimental/investigational or unproven.

U of U Health Plans considers central DEXA scan (77080) medically necessary when used as a non-screening or monitoring tool when the member has any of the following indications:

- A. Prior to and during pharmacologic treatment for osteoporosis
- B. Prolonged use of medications associated with low bone mass or bone loss (e.g., anticonvulsants, heparin, lithium, gonadotropin-releasing hormone agonists)
- C. Child or adolescent with a disease process known to adversely affect the skeleton
- D. Primary hyperparathyroidism
- E. Celiac sprue
- F. Known osteoporotic fracture
- G. History of pathologic fracture
- H. History of low-impact fracture
- I. Vertebral abnormalities as demonstrated by an x-ray to be indicative of osteoporosis, osteopenia, or vertebral fracture
- J. Adults (age 18 years and older) with spinal cord injury resulting in permanent motor or sensory dysfunction
- K. Receiving (or expected to receive) systemic glucocorticoid therapy equivalent to prednisone at least 5 mg per day for greater than 3 months
- L. Women with Turner syndrome

Computed tomography (CT) (CPT® 77078) for bone mineral density measurement testing is considered medically necessary as a screening tool for osteoporosis when DEXA scanner is unavailable or known to be inaccurate for ANY of the following indications:

- A. Women \geq 65 years of age and men \geq 70 years of age
- B. Younger postmenopausal women, women in the menopausal transition, and men aged 50 to 69 years with clinical risk factors for fracture
- C. Adults who have a fracture at age 50 years and older
- D. Adults with a condition (e.g., rheumatoid arthritis, organ transplant) or taking a medication (e.g., glucocorticoids, aromatase inhibitors, androgen deprivation therapy) associated with low bone mass or bone loss

U of U Health Plans does NOT cover non-screening or monitoring of bone mineral density measurement for any other indication (e.g., evaluation of osteoporosis/osteoporotic fractures in persons with schizophrenia who are on anti-psychotic medications, and monitoring individuals who are on anti-depressive agents) as it is considered experimental/investigational or unproven.

U of U Health Plans does NOT cover trabecular bone score (TBS) (77089-77092) for any indication as there is insufficient evidence in the published medical literature to demonstrate the safety, efficacy and long term outcomes. Therefore, TBS is considered experimental/investigational or unproven.

U of U Health Plans does NOT cover pulse-echo ultrasound (76999) for bone mineral density measurement testing as it is considered experimental, investigational or unproven.

U of U Health Plans does NOT cover ultrasound-based Radiofrequency Echographic Multi-Spectrometry (REMS) (0815T) for bone density study and/or fracture-risk assessment as it is considered experimental, investigational or unproven.

2. Medicaid Plans

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at: <https://medicaid.utah.gov/utah-medicaid-official-publications/> or the [Utah Medicaid code Look-Up tool](#)

CPT/HCPCS codes covered by Utah State Medicaid may still require further evaluation to determine medical necessity for coverage.

Clinical Rationale

A 2016 systematic review (Lee et al) was conducted to compare the diagnostic accuracy of vertebral fracture assessment with densitometry (VFA) and dual X-ray absorptiometry (DEXA) for identification of vertebral fractures (VFs), from their inception to May 2013. VFA appeared to have moderate sensitivity and high specificity for detecting VFs when compared with spinal radiography. VFs are recognized as the hallmark of osteoporosis, and a previous VFs increases the risk of a future fracture. Comparison was done by analyzing the sensitivity and specificity using a 2 x 2 contingency table. Subgroup analyses were also performed on studies with a low risk of bias and applicability. Twelve studies were analyzed for the diagnostic accuracy of VFA. The sensitivity and specificity were 0.70-0.93 and 0.95-1.00, respectively, analyzed on a per-vertebra basis, and 0.65-1.00 and 0.74-1.00 on a per-patient basis. The sensitivity and

specificity of five studies in subgroups with a low risk of bias in the intervention test were 0.70-0.84 and 0.96-0.99, respectively. In studies with a low risk of bias in the patient selection, those based on a per-vertebra basis in three studies were 0.70-0.93 and 0.96-1.00, respectively. The authors concluded that VFA had moderate sensitivity and high specificity for detecting VFs when compared with DEXA. However, the present findings are insufficient to assess whether DEXA should be replaced by VFA. Therefore, further more robust studies are needed to confirm these findings.

In UpToDate's overview of dual-energy x-ray absorptiometry (DEXA) the authors found the following for diagnosis of osteoporosis – The World Health Organization (WHO) has established a classification of BMD according to T-score that is the worldwide standard for diagnosis of osteoporosis. The WHO criteria should be used for diagnostic classification in postmenopausal females, perimenopausal females, and for males age 50 years and older. They should not be used for premenopausal females, males under age 50 years, or children. In these populations, Z-scores rather than T-scores should be used. As for the skeletal site selection – The Bone Health and Osteoporosis Foundation (BHOFF) and the International Society for Clinical Densitometry (ISCD) recommend that the diagnosis of osteoporosis be made using the lowest T-score measured by DEXA of the lumbar spine (L1-L4), total proximal femur, femoral neck, or one-third radius. The WHO and the ISCD recommend the use of the National Health and Nutrition Examination Survey (NHANES) III young adult reference database for calculation of T-score at the hip, using a White female database for females and for males. Application of this recommendation may vary according to local requirements. Also, the same DEXA instrument should be used for serial BMD testing whenever possible. As it is not possible to quantify BMD changes on measurements made on different instruments unless a cross-calibration study has been done. And finally, identification of previously undetected vertebral fractures (VFs) may change the diagnostic classification, fracture risk assessment, and clinical management. Vertebral fracture assessment (VFA) by DEXA is a method of visualizing the spine to detect VFs. VFA compares favorably with spine radiographs in detecting moderate and severe VFs, but it does not perform as well for diagnosing mild VFs.

In 2023, Hayes evaluated “the effectiveness and safety of the trabecular bone score (TBS) as an adjunct to bone mineral density (BMD) measurement and/or other validated tools incorporating patient information for prediction of fracture risk and guidance of preventive treatment in postmenopausal women. The evidence base comprised 8 cohort studies; 5 were prospective and 3 were retrospective. Studies were designed to assess improvement in the accuracy of fracture prediction when TBS was combined with BMD, with BMD and other risk factors, or with fracture risk assessment tool (FRAX) scores. The reference standard for fracture prediction was the occurrence of new fractures during the study follow-up period.” The review concluded, a low-quality body of inconstant evidence did not demonstrate that the use of TBS improves the accuracy of fracture prediction as an adjunct to BMD or FRAX score. Small and inconsistent increases in accuracy were seen with adjunct TBS, which raises concerns about whether use of TBS will provide meaningful improvements in management of postmenopausal women at risk for fragility fractures; however, no studies of the clinical utility of TBS were identified. Thus, further more robust studies are needed to evaluate clinical utility and to determine whether combining TBS with BMD or FRAX score provides clinically meaningful improvements in fracture prevention in postmenopausal women, and to evaluate the adjunct use of the TBS on health outcomes.

Also in 2023, Hayes conducted an Evidence Analysis Research Brief to summarize the volume of publications and to determine whether there is adequate published peer-reviewed literature to evaluate the evidence related to quantitative computed tomography (QCT) compared with dual-energy x-ray absorptiometry (DEXA) for screening of osteopenia or osteoporosis in postmenopausal female persons. Six cross-sectional studies evaluating QCT for the screening of osteopenia or osteoporosis were

identified. No systematic reviews with or without meta-analysis were identified. No clinical utility studies evaluating QCT for screening of osteopenia or osteoporosis were identified. Six position statements or guidelines were identified. Based on a review of full-text clinical practice guidelines and position statements, guidance appears to confer weak support for QCT for screening of osteopenia or osteoporosis in postmenopausal female persons. The review of abstracts suggests that there is adequate published peer-reviewed literature to evaluate the evidence related to QCT for screening of osteopenia or osteoporosis in postmenopausal female persons.

The Endocrine Society guidelines on Osteoporosis in Men recommend vertebral fracture assessment (VFA) using DEXA equipment for men with osteopenia or osteoporosis who might have previously undiagnosed vertebral fractures. If VFA is technically limited or not available, lateral spine radiographs should be considered (Watts, 2012).

There is adequate evidence to support the use of central bone density studies to assess the risk of osteoporosis in settings where the results may influence medical therapy. Studies have demonstrated the efficacy of bone mineral studies for several populations at higher risk for this process, including postmenopausal women, especially those over the age of 65, individuals currently receiving medications for osteoporosis prophylaxis, those receiving glucocorticoid therapy and individuals with endocrinopathies or other conditions which predispose to osteoporosis. Examples of these include: hyperthyroidism and hypothyroidism, hyperparathyroidism, corticosteroid use, and rheumatoid arthritis. Currently both the American Association of Clinical Endocrinologist (AACE) Medical Guidelines for Clinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis (Camacho, 2020) and the U.S. Preventive Services Task Force (USPSTF) statement on Osteoporosis to Prevent Fractures: Screening (2018) recommend a screening BMD scan for all women over the age of 65 (USPSTF B recommendation). The American College of Obstetricians and Gynecologists (ACOG) recommends screening for osteoporosis in postmenopausal patients 65 years and older with BMD testing by way of DEXA scan to prevent osteoporotic fractures (strong recommendation, high-quality evidence). Regarding individuals at increased risk for osteoporosis, as determined by a formal clinical risk assessment tool, ACOG recommends that screening be conducted using BMD testing by way of DEXA scan to prevent osteoporotic fractures in postmenopausal patients younger than 65 years (strong recommendation, high-quality evidence) (ACOG, 2021).

As far as additional testing after the initial screening, ACOG recommends that after treatment has been initiated, one DEXA scan 1 – 2 years later can be used to assess the effect of treatment. If the BMD is improved or stable (no significant change), and there are no new risk factors, the DEXA does not usually need to be repeated (ACOG, 2021). This is based upon the results of several trials that evaluated the change in BMD in individuals undergoing therapy for various conditions. These studies found that change in bone density could not be meaningfully assessed until late in the second year of therapy because some individuals actually continue to lose bone density during the first year but have subsequent significant increases during the second year of therapy. Alternatively, the AACE recommends BMD monitoring for individuals undergoing therapy for osteoporosis prevention every 1 to 2 years until bone mass is stable, then, continue with follow-up DEXA every 1 - 2 years or at a less-frequent interval, depending on clinical circumstances (ACR, 2021; Camacho, 2020; Eastell, 2019).

The use of images other than DEXA are proposed to identify individuals at high risk of fracture, or identify those with subclinical vertebral fractures. There is an increasing interest in performing concurrent bone health screening on patients who undergo diagnostic CT scans of the abdomen and pelvis. Additionally, digital X-ray radiogrammetry (DXR) is proposed to estimate hand BMD from hand x-ray images. Studies by Kolanu, et al., 2020 [Zebra Medical Vision®]; Dagan, et al., 2020 [HealthVCF]; Allaire, et al., 2019 [VirtuOst]; Adams, et al., 2018 [VirtuOst]; Kälvesten, et al., 2016 and Wilczek, et al.,

2013 [OneScreen, Sectra]; Bach-Mortensen, et al., 2006 [X-posure System™ Sectra Pronosco A/S] have all been published. There is a lack of well-designed clinical trials addressing the impact of algorithmic-based assessments of non-DEXA scans on patient-specific long-term health outcomes and thus conclusions cannot be reached as it relates to comparative accuracy, and safety of these methodologies in performance of osteoporosis screening.

Pulse-echo ultrasound (CPT® 76999) measures apparent cortical bone thickness at the proximal tibia and can be used in conjunction with other clinical risk factors or patient characteristics as an aid to the physician in the diagnosis of osteoporosis and other medical conditions leading to reduced bone strength and in the determination of fracture risk.

Lewiecki in 2020, Karjalainen et al in 2018 and Schousboe et al in 2017 all published studies assessing the utility of this method for assessing for osteoporosis. Though suggestive of potential utility, the peer-reviewed scientific literature lacks well-designed studies evaluating the impact of utilizing pulse-echo ultrasound on long-term health outcomes.

Multiple studies have been performed to assess the sensitivity and specificity of REMS in assessing for osteoporosis. These include studies by Al Refaie et al., 2023, Lalli, et al., 2022, Cortet, et al., 2021 and Adami, et al., 2021. Each study has significant limitations. There is a lack of well-designed clinical trials including diverse populations in the peer-reviewed scientific literature addressing the impact of the use of REMS on long-term patient health outcomes.

There is a lack of well-designed clinical trials including diverse populations in the peer-reviewed scientific literature addressing the impact of TBS iNsight® (Med-Imaps) on patient-specific health outcomes. Future prospective trials evaluating the use trabecular bone score in place of or in addition to established fracture prediction tools should report if long-term patient health outcomes are improved (McCloskey, et al., 2015; Leslie, et al., 2014; Hans, et al., 2011).

Applicable Coding

CPT Codes

Possibly covered (if criteria are met)

- | | |
|--------------|---|
| 77078 | Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (eg, hips, pelvis, spine) |
| 77080 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine) |
| 77081 | ; appendicular skeleton (peripheral) (eg, radius, wrist, heel) |
| 77085 | ; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment |
| 77086 | Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA) |

Not covered

- | | |
|--------------|--|
| 76977 | Ultrasound bone density measurement and interpretation, peripheral site(s), any method |
|--------------|--|

- 77089** Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk
- 77090** Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere
- 77091** Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only
- 77092** Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional
- 76999** Unlisted ultrasound procedure (e.g., diagnostic, interventional)[when used to report pulse-echo ultrasound for bone density measurement testing
- 0554T** Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report
- 0555T** ; retrieval and transmission of the scan data
- 0556T** ; assessment of bone strength and fracture risk and bone mineral density
- 0557T** ; interpretation and report
- 0558T** Computed tomography scan taken for the purpose of biomechanical computed tomography analysis
- 0691T** Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report
- 0743T** Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report
- 0749T** Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report;
- 0750T** ; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD

0815T Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine

HCCPS Codes

Not covered

G0130 Single energy X-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)

References:

1. Adami G, Arioli G, Bianchi G, Brandi ML, Caffarelli C, Cianferotti L, Gatti D, Girasole G, Gonnelli S, Manfredini M, Muratore M, Quarta E, Quarta L. Radiofrequency echographic multi spectrometry for the prediction of incident fragility fractures: A 5-year follow-up study. *Bone*. 2020 May;134:115297.
2. Adams AL, Fischer H, Kopperdahl DL, Lee DC, Black DM, et al. Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). *J Bone Miner Res*. 2018 Jul;33(7):1291-1301.
3. Al Refaie A, Baldassini L, Mondillo C, Giglio E, De Vita M, Tomai Pitinca MD, Gonnelli S, Caffarelli C. Radiofrequency Echographic Multi Spectrometry (R.E.M.S.): New Frontiers for Ultrasound Use in the Assessment of Bone Status-A Current Picture. *Diagnostics (Basel)*. 2023 May 9;13(10):1666.
4. Allaire BT, Lu D, Johannesdottir F, Kopperdahl D, Keaveny TM, et al. Prediction of incident vertebral fracture using CT-based finite element analysis. *Osteoporos Int*. 2019 Feb;30(2):323-331.
5. American Association of Clinical Endocrinologists (AACE) and American Association of Endocrine Surgeons (AAES) position statement on the diagnosis and management of primary hyperparathyroidism. AACE/AAES Task Force on Primary Hyperparathyroidism. *Am J Gastroenterol*. 2005; 11(1):49-54.
6. American College of Obstetricians and Gynecologists' Committee on Clinical Practice Guidelines–Gynecology. Osteoporosis prevention, screening, and diagnosis: ACOG clinical practice guideline No. 1. *Obstet Gynecol*. 2021; 138(3):494-506. Accessed July 30, 2024. Available at: https://journals.lww.com/greenjournal/fulltext/2021/09000/osteoporosis_prevention_screening_and_diagnosis_30.aspx
7. Bach-Mortensen P, Hyldstrup L, Appleyard M, Hindsø K, Gebuhr P, Sonne-Holm S. Digital x-ray radiogrammetry identifies women at risk of osteoporotic fracture: results from a prospective study. *Calcif Tissue Int*. 2006 Jul;79(1):1-6.
8. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College Of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. *Endocr Pract*. 2020; 26(Suppl 1):1-46.
9. Cortet B, Dennison E, Diez-Perez A, Locquet M, Muratore M, Nogués X, Ovejero Crespo D, Quarta E, Brandi ML. Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis in a European multicenter clinical context. *Bone*. 2021 Feb;143:115786. doi: 10.1016/j.bone.2020.115786. Epub 2020 Dec 2. PMID: 33278653.
10. Dagan N, Elnekave E, Barda N, Bregman-Amitai O, Bar A, et al. Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization. *Nat Med*. 2020 Jan;26(1):77-82.
11. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2019; 104(5):1595-1622.
12. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. *J Bone Miner Res*. 2011 Nov;26(11):2762-9.
13. Hayes, Inc. (2023) Health Technology Assessment. "Trabecular Bone Score to Predict Fracture Risk in Postmenopausal Patients". January 11, 2023. Accessed: December 19, 2023. Available at: <https://evidence.hayesinc.com/report/hta.trabecular5283>
14. Hayes, Inc. (2023). Evidence Analysis Research Brief. "Quantitative Computed Tomography Versus Dual-Energy X-Ray Absorptiometry for Screening of Osteopenia or Osteoporosis in Postmenopausal Female Persons". November 21, 2023. Accessed: December 19, 2023. Available at: <https://evidence.hayesinc.com/report/earb.qctscreening5641>
15. Kälvesten J, Lui LY, Brismar T, Cummings S. Digital X-ray radiogrammetry in the study of osteoporotic fractures: Comparison to dual energy X-ray absorptiometry and FRAX. *Bone*. 2016 May;86:30-5.
16. Karjalainen JP, Riekkinen O, Kröger H. Pulse-echo ultrasound method for detection of post-menopausal women with osteoporotic BMD. *Osteoporos Int*. 2018 May;29(5):1193-1199. doi: 10.1007/s00198-018-4408-x. Epub 2018 Feb 19. PMID: 29460101.

17. Kolanu N, Silverstone EJ, Ho BH, Pham H, Hansen A, Pauley E, et al. Clinical Utility of Computer-Aided Diagnosis of Vertebral Fractures From Computed Tomography Images. *J Bone Miner Res*. 2020 Dec;35(12):2307-2312.
18. Lalli P, Mautino C, Busso C, Bardesono F, Di Monaco M, Lippi L, Invernizzi M, Minetto MA. Reproducibility and Accuracy of the Radiofrequency Echographic Multi-Spectrometry for Femoral Mineral Density Estimation and Discriminative Power of the Femoral Fragility Score in Patients with Primary and Disuse-Related Osteoporosis. *J Clin Med*. 2022 Jun 29;11(13):3761. doi: 10.3390/jcm11133761. PMID: 35807046; PMCID: PMC9267756.
19. Lee JH, Lee YK, Oh SH, et al. A systematic review of diagnostic accuracy of vertebral fracture assessment (VFA) in postmenopausal women and elderly men. *Osteoporos Int*. 2016; 27(5):1691-1699.
20. Leijten AD, Hampsink B, Janssen M, et al. Can digital X-ray radiogrammetry be an alternative for dual-energy X-ray absorptiometry in the diagnosis of secondary low bone quality in children? *Eur J Pediatr*. 2019; 178(9):1433-1441.
21. Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D. Lumbar spine texture enhances 10-year fracture probability assessment. *Osteoporos Int*. 2014 Sep;25(9):2271-7.
22. Lewiecki EM. Pulse-echo Ultrasound Identifies Caucasian and Hispanic Women at Risk for Osteoporosis. *J Clin Densitom*. 2021 Apr-Jun;24(2):175-182. doi: 10.1016/j.jocd.2020.04.002. Epub 2020 May 11. PMID: 32527649.
23. Lin W, He C, Xie F, Chen T, Zheng G, Yin H, Chen H, Wang Z. Quantitative CT screening improved lumbar BMD evaluation in older patients compared to dual-energy X-ray absorptiometry. *BMC Geriatr*. 2023 Apr 17;23(1):231. doi: 10.1186/s12877-023-03963-6. PMID: 37069511; PMCID: PMC10108496.
24. McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Kanis JA. Adjusting fracture probability by trabecular bone score. *Calcif Tissue Int*. 2015 Jun;96(6):500-9.
25. Rajan, R., K. E. Cheria, N. Kapoor and T. V. Paul (2020). "Trabecular Bone Score-An Emerging Tool in the Management of Osteoporosis." *Indian J Endocrinol Metab* 24(3): 237-243.
26. Schousboe JT, Riekkinen O, Karjalainen J. Prediction of hip osteoporosis by DXA using a novel pulse-echo ultrasound device. *Osteoporos Int*. 2017;28(1):85-93.
27. U.S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force recommendation statement. *JAMA*. 2018; 319(24):2521-2531.
28. UpToDate®. "Overview of Dual-energy X-ray Absorptiometry" Last topic update: December 2, 2021. Literature current though: November 2023. Accessed: December 19, 2023. Available at: https://www.uptodate.com/contents/overview-of-dual-energy-x-ray-absorptiometry?search=Trabecular%20bone%20score&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#
29. USPSTF Osteoporosis to Prevent Fractures: Screening, Update Draft (accessed August 24, 2024) <https://www.uspreventiveservicestaskforce.org/uspstf/draft-update-summary/osteoporosis-screening-prevent-fractures>
30. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2012; 97(6):1802–1822.
31. Wilczek ML, Kälvesten J, Algulin J, Beiki O, Brismar TB. Digital X-ray radiogrammetry of hand or wrist radiographs can predict hip fracture risk—a study in 5,420 women and 2,837 men. *Eur Radiol*. 2013 May;23(5):1383-91.

Disclaimer:

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

“University of Utah Health Plans” and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.